These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 12132788

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
    Luna-Chadid M, Pérez Calle JL, Mendoza JL, Vera MI, Bermejo AF, Sánchez F, López San Román A, Froilán C, González-Lara V, García-Paredes J, Fernández-Blanco I, Abreu L, Casis B, Solís Herruzo JA, Gisbert JP, Maté Jiménez J.
    Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
    [Abstract] [Full Text] [Related]

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 4. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
    Schröder O, Blumenstein I, Schulte-Bockholt A, Stein J.
    Aliment Pharmacol Ther; 2004 Feb 01; 19(3):295-301. PubMed ID: 14984376
    [Abstract] [Full Text] [Related]

  • 5. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.
    N Engl J Med; 2004 Feb 26; 350(9):876-85. PubMed ID: 14985485
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response to infliximab is related to disease duration in paediatric Crohn's disease.
    Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, Dé Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A.
    Aliment Pharmacol Ther; 2003 Aug 15; 18(4):425-31. PubMed ID: 12940928
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM, Perry CM.
    BioDrugs; 2002 Aug 15; 16(2):111-48. PubMed ID: 11985485
    [Abstract] [Full Text] [Related]

  • 13. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 15; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group.
    Lancet; 2002 May 04; 359(9317):1541-9. PubMed ID: 12047962
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.
    Sands BE, Blank MA, Patel K, van Deventer SJ, ACCENT II Study.
    Clin Gastroenterol Hepatol; 2004 Oct 04; 2(10):912-20. PubMed ID: 15476155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.